Navigation Links
Treatment in Biological Technology

Nile Therapeutics, Inc. Announces Dosing of First Patient in Phase 2 Study of CD-NP for the Treatment of Acute Heart Failure

SAN FRANCISCO, Aug. 4 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX ), a company focused on the development of novel therapeutics for heart failure patients, today announced dosing of its first patient in a Phase 2 clinical study of its lead product, CD-NP, for the treatme...

DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD

PRINCETON, N.J., Aug. 4 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc., (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biopharmaceutical company, announced today that the Office of Orphan Products Development of the United States Food and Drug Administration (FDA) has granted Or...

Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab

BETHESDA, Md., Aug. 3 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it has received Orphan Drug Designation from the Europ...

AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma

QUEBEC CITY, Aug. 3 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS , TSX: AEZ), ("the Company") a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ), its partner and licensee for perifosi...

Varian Medical Systems to Showcase a Wide Spectrum of New and Updated Products That Improve Radiotherapy Treatment Processes at 2009 AAPM Meeting

ANAHEIM, Calif., July 23 /PRNewswire-FirstCall/ -- Varian Medical Systems (NYSE: VAR ) will showcase a wide spectrum of new and updated products that improve and simplify the processes of radiotherapy and radiosurgery. Among the products on display will be a new version of the Ec...

Tobira Therapeutics Inc. Announces Phase I Data Demonstrating Pharmacokinetic Properties of TAK-652 for the Treatment of HIV

PRINCETON, N.J. and SAN DIEGO, July 22 /PRNewswire/ -- Tobira Therapeutics Inc., a clinical stage biotechnology company committed to research and product discovery for the treatment of life-threatening and life-altering infectious diseases, today announced pharmacokinetic data and result...

Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting

LAGUNA NIGUEL, Calif., July 14 /PRNewswire/ -- Inspiration Biopharmaceuticals today announced the presentation of positive preclinical safety, toxicology and preliminary pharmacokinetic data on its lead product, IB1001, a novel recombinant Factor IX product to treat patients with he...

REMERON(R) Now Approved in Japan for the Treatment of Depression in Adult Patients

KENILWORTH, N.J., July 9 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) today announced that Schering-Plough K.K., the company's country operation in Japan, has received marketing approval for REMERON(R) /Reflex(R) (mirtazapine)15 mg Tablets for the treatment of major depress...

Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity

SAN DIEGO, July 9 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) today announced positive results from a 28-week dose-ranging study of pramlintide/metreleptin, a combination treatment comprising pramlintide, an analog of the natural hormone amylin, and metreleptin, an ana...

Data Published in The New England Journal of Medicine Support Use of Raxibacumab (ABthrax(TM)) for the Treatment of Inhalation Anthrax

ROCKVILLE, Md., July 9 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI ) today announced publication by The New England Journal of Medicine of the results of two pivotal animal efficacy studies, which showed the life-saving potential of the Company's human monoclonal an...

Mylan Receives FDA Approval for Generic Version of Prostate Cancer Treatment Casodex(R)

PITTSBURGH, July 7 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL ) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Bicalutamide Tablets, 50 mg. Bical...

Bion Announces Approval of New U.S. Patent that Broadens Protection for the Company's Livestock Waste Environmental Treatment Processes

NEW YORK, June 30 /PRNewswire-FirstCall/ -- Bion Environmental Technologies, Inc. (OTC Bulletin Board: BNET) announced today that it was notified that its U.S. Patent application 11/592,513 entitled "Low Oxygen Biologically Mediated Nutrient Removal" has been approved. The patent application was m...

Yaupon Therapeutics Completes Patient Enrollment for Pivotal Phase 2 Study of Clearazide for Treatment of Cutaneous T-cell Lymphoma

Largest clinical study ever involving patients with cutaneous T-cell lymphoma on schedule for completion in June 2010 RADNOR, Pa., June 29 /PRNewswire/ -- Yaupon Therapeutics, a privately held specialty pharmaceutical company, has announced it has completed enrollment for a pivotal Phase 2 c...

Palkion Selects Novel Oral Development Candidate for the Treatment of Anemia

SAN DIEGO, June 29 /PRNewswire/ -- Palkion, Inc. announced today that it has initiated preclinical development studies for its orally available anemia therapeutic candidate that modulates the Hypoxia-Inducible Factor Prolyl Hydroxylase (HIF-PH) enzyme system. In February 2008, Palkion was founded ...

Genomic Health Reports Favorable Commentary on Value of Multigene Assays From the St. Gallen Expert Consensus Meeting on the Primary Treatment of Early Breast Cancer

- Guidelines Specify that Validated Molecular Assays Should be Considered as an Adjunct to Standard Measures in Helping Determine Chemotherapy Benefit - GENEVA, and REDWOOD CITY, Calif., June 26 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX ) today reported that the St. Galle...

Varian Medical Systems Acquires Assets of IKOEmed and IKOEtech; Acquisition to Add Software for Accelerating Radiotherapy Treatment Planning

PALO ALTO, Calif., June 25 /PRNewswire-FirstCall/ -- Varian Medical Systems, Inc., (NYSE: VAR ) today announced it has acquired the assets of Houston-based IKOEmed and IKOEtech, privately-owned suppliers of software used in the planning of radiotherapy and radiosurgery treatments. The acq...

CEL-SCI Files Patent Application to Support Company's Treatment for More Virulent Strain of H1N1 Swine and Other Influenza Viruses

VIENNA, Va., June 24 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION (NYSE AMEX: CVM ) announced today that it has filed a provisional U.S. patent application covering its L.E.A.P.S.(TM) immune therapy drugs (vaccines) for the prevention/treatment of H1N1, swine, bird flu, Influenza A and/or ev...

Innocoll Announces Provisional Findings From Its Three Phase 2 Clinical Trials Investigating CollaRx(R) GENTAMICIN TOPICAL for the Treatment and Prevention of Diabetic Foot Infections

ASHBURN, Va., June 18 /PRNewswire/ -- Innocoll, Inc., a privately-held biopharmaceutical company, announced positive provisional findings from its three phase 2 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx(R) GENTAMICIN TOPICAL for the...

Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours

LAUSANNE, Switzerland and TAMPA, Florida, June 18 /PRNewswire/ -- Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, and Moffitt Cancer Center (Moffitt), a non-profit Fl...

Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer

- Dosimetry Study Results Show Greater Than 300-Fold More Radiation Delivered to Tumor as Compared to Other Normal Organs - - All Patients in the First Two Cohorts Have Met or Exceeded the Expected Median Survival Time for Recurrent GBM Patients - TORONTO and TUSTIN, Calif., June ...

Three Rivers Announces Positive Results from Phase 3 DIRECT Trial of Once-Daily INFERGEN(R) with Ribavirin in Hepatitis C Virus Treatment Failures

WARRENDALE, Pa., June 16 /PRNewswire/ -- Three Rivers Pharmaceuticals announced today positive results of the U.S.-based, randomized Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy (DIRECT) clinical trial authored by Bruce R. Bacon, M.D., of Saint Louis University , an...

NeoStem Signs Agreement with Shanghai Corporation to Develop A Stem Cell Collection and Treatment Network in Shanghai, Taiwan and Other Targeted China Provinces

NEW YORK, June 15 /PRNewswire-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS ), which is pioneering the pre-disease collection, processing and long-term storage of adult stem cells for future medical need, announced today it has signed an exclusive 10-year agreement with Enhance BioMedical Holdings...

Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients

NEW YORK, June 8 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) today announced results of the Phase 2 study of Zerenex (ferric citrate) for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on thri...

ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema

- Company Also Granted Expansion of Prophylaxis Therapy Label to Include Patient Labeling for Self-Administration - EXTON, Pa., June 4 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM ) today announced that it has received a Complete Response letter from the U.S. Food and Dr...

Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI

SAN DIEGO, June 2 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ) announced that additional results from its North American Phase 3 clinical study of fidaxomicin in patients with Clostridium difficile infection (CDI) were presented today by clinical investigator, Mark A...

OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer

Webcast at 7:10 p.m. Eastern Time Today BOTHELL, WA, and VANCOUVER, May 30 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI ) today announced the final results of a Randomized Phase 2 Trial presented during an oral presentation at the American Society of Clinical Oncol...

OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial

BOTHELL, WA, and VANCOUVER, May 30 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI ) today announced preliminary results of a Phase 1 trial presented during an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting. Preliminary results as of A...

Dey L.P. to Market EMSAM(R) Skin Patch for Treatment of Major Depressive Disorder

PITTSBURGH, May 29 /PRNewswire-FirstCall/ -- Dey L.P., a subsidiary of Mylan Inc. (Nasdaq: MYL ), today announced that it has begun to market and distribute EMSAM(R) in the U.S. EMSAM, a selegiline transdermal system, is a monoamine oxidase inhibitor (MAOI), which was approved by the U.S. Food a...

CEL-SCI Developing Immune-Based Treatment Against Swine and Other H1N1 Flu Viruses Using Proprietary L.E.A.P.S. Technology

VIENNA, Va. May 26 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE AMEX: CVM ) announced today that it is developing an immune-based treatment for the "swine flu and related H1N1" flu viruses, utilizing its proprietary L.E.A.P.S.(TM) (Ligand Epitope Antigen Presentation System) vaccine tec...

Low Occurrence of Severe Cardiac Side Effects Despite Extensive Prior Doxorubicin Treatment Reported in Pixantrone Pivotal Trial

Updated Safety data presented at BIO International Convention in Atlanta ATLANTA, May 19 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) released updated safety data today from its pixantrone phase III 301 EXTEND trial demonstrating the effectiveness of pixantr...

Savient Announces New Date for FDA Arthritis Advisory Panel Review of KRYSTEXXA(TM) for Treatment Failure Gout

EAST BRUNSWICK, N.J., May 7 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT ) today announced that its biologics license application (BLA) for KRYSTEXXA (TM) (pegloticase), a novel biological drug for treatment failure gout (TFG) patients, will be reviewed by the Arthritis...

Disability and Poor Quality of Life Associated With Treatment Failure Gout Patients

New Study Published in the Journal of Rheumatology Examines Quality of Life and Disability in Treatment Failure Gout Patients EAST BRUNSWICK, N.J., May 5 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT ) announced today the print publication of the Savient-supported lo...

ChartTrends(R): Bone and Mineral Metabolism in Dialysis Reveals Latest Trends in the Treatment of Calcium, Phosphorus and PTH

EXTON, Pa., April 30 /PRNewswire/ -- BioTrends Research Group, Inc. released ChartTrends (R) : Bone and Mineral Metabolism in Dialysis, a syndicated publication offering comprehensive insight into the management of calcium, phosphorus and PTH in dialysis patients. The report is based on actua...

BioSpecifics Technologies Corp. Announces FDA Acceptance of Biologics License Application With Priority Review for XIAFLEX(TM) for the Treatment of Dupuytren's Disease

LYNBROOK, N.Y., April 28 /PRNewswire-FirstCall/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC ), a biopharmaceutical company developing first in class collagenase-based products, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (B...

FDA has Granted HUD (Humanitarian Use Device) Designation to ITGI's Pericardium Covered Stents, Over and Under(R) and Aneugraft(R), for Treatment of Perforations and Dissections of Native Coronary Arteries and Saphenous Vein Grafts

OR AKIVA, Israel, April 28 /PRNewswire-FirstCall/ -- ITGI Medical, Ltd. (TASE: ITGI) a company engaged in research, development, manufacturing and marketing of heterologous tissue covered stents, announced that the US Food and Drug Administration (FDA) has granted HUD (Humanitarian Use Device)...

PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research

ANNAPOLIS, Md., April 28 /PRNewswire/ -- PharmAthene, Inc. (NYSE Amex: PIP ), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that results from a second Phase II study of SparVax(TM) were presented yesterday at the 12th Annual Conf...

SeqWright Expands into the Genetically-Targeted Therapy Field by Partnering with PharmaGenoma to Provide Next-Generation Hair Loss Treatment Genetic Testing

HOUSTON, April 28 /PRNewswire/ -- SeqWright Inc., a CLIA certified and GLP compliant provider of custom genomic and molecular biology services, announced today its entry into the genetically-targeted therapy field through its partnership with PharmaGenoma. SeqWright will be the exclusive genetic ...

OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer

FDA confirms durable pain palliation as an acceptable primary endpoint for a regulatory submission in support of market approval BOTHELL, WA, April 28 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI ) announced today that the company has reached an agreement...

CEL-SCI Presents Data at Prestigious Medical Conference Demonstrating That Its L.E.A.P.S. Technology Stimulates Maturation of Human Blood Cells Into Dendritic Cells Suggesting Potential for Prevention and Treatment of Infectious Disease

Technology also has potential to fight cancer, rheumatoid arthritis, as well as enhance the effectiveness of vaccines VIENNA, Va., April 27 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE Amex: CVM ) announced today the presentation of data at the 11th annual National Foundation of Infe...

Z Therapy Is The First In North Texas To Offer Revolutionary Treatment Option For Neck Pain Sufferers

Z Therapy Whiplash Treatment Center now offers a ground-breaking treatment option for victims of whiplash associated disorders (WAD). With the introduction of a multi-cervical unit (MCU) by BTE Technologies, Z Therapy is the first and only rehabilitation specialist in North Texas to offer this t...
Other Tags
(Date:10/16/2014)... tract infections and worldwide claims the lives of ... Ghent University have succeeded in developing a promising ... , Xavier Saelens (VIB/UGent): "We discovered a ... the development of a novel approach to vaccination ... numerous small children and elderly people." , ...
(Date:10/15/2014)... ,Models of Life, is a non-traditional biophysics textbook and ... book is a journey of discovery into biological systems ... and biological regulation. It is about how our genes ... between the billions of cells in an organism. It ... between principles, which can be found on both large ...
(Date:10/15/2014)... will be awarded the 44th Rosenstiel Award for Distinguished ... pioneering research exploring the mechanisms of genomic instability and ... Alt is the second alumnus to win the Rosenstiel ... in 2003. , Alt is the Charles A. Janeway ... Medical School and an investigator at the Howard Hughes ...
Breaking Biology News(10 mins):New perspectives for development of an RSV vaccine 2New book about life as seen from physics 2Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2
(Date:10/22/2014)... Los Angeles, California (PRWEB) October 22, 2014 ... Recovery 2.0: Move Beyond Addiction and Upgrade Your Life (Paperback; ... the field of Yoga & Recovery. This book is ... and thrive in a life of recovery. , Recovery ... of the 12 Steps; Recovery 2.0 is a guide for ...
(Date:10/22/2014)... Best Cheap Hosting USA is among ... site has recently announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) ... from around the world. , “iPower is one of ... is providing various kinds of useful products for new ... offering excellent customer service and a number of features ...
(Date:10/22/2014)... Although there are only 24 hours in a day, ... have trouble finding time within their busy schedules for exercise and ... of time to get in shape. Here are five ways you ... , Change Up Your Commute , Consider riding a bike ... exercise into your daily routine. If you must use your car ...
(Date:10/22/2014)... WALTHAM, MA (PRWEB) October 22, 2014 ... developing new solutions for the treatment of bacterial infections, ... J. Sinskey has joined its board of directors. ... Microbiology and Engineering Systems at The Massachusetts Institute of ... the MIT faculty since 1968. Dr. Sinskey also holds ...
(Date:10/22/2014)... -- Two sisters in high school have developed ways ... Medha Krishen use electronic stethoscopes, which electronically amplify body ... patterns or heartbeats. Ilina, a senior at Port ... a way to detect early lung damage in people ... Ilina recorded one breath cycle each from 16 smokers, ...
Breaking Medicine News(10 mins):Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2
Other Contents